2915-16-4Relevant articles and documents
Utilizing triazine/pyrimidine acceptor and carbazole-triphenylamine donor based bipolar novel host materials for highly luminescent green phosphorescent OLEDs with lower efficiency roll-off
Braveenth, Ramanaskanda,Ahn, Dae Hyun,Han, Ji-Hun,Moon, Ji Su,Kim, Si Woo,Lee, Hyuna,Qiong, Wu,Kwon, Jang Hyuk,Chai, Kyu Yun
, p. 377 - 384 (2018)
In this work, two novel bipolar host materials were designed, synthesized and applied in green phosphorescent based OLEDs. Both the host materials, 4-(2-(4,6-diphenyl-1,3,5-triazin-2-yl)-9H-carbazol-9-yl)-N,N-diphenylaniline (TRZ 1) and 4-(2-(4,6-diphenylpyrimidin-2-yl)-9H-carbazol-9-yl)-N,N-diphenylaniline (PYR 1) exhibited high thermal stability, with decomposition temperatures of 425 °C and 400 °C, respectively. The triplet energy of PYR 1 (2.63 eV) was higher than that of TRZ 1 (2.44 eV), and facilitated suitable energy transfer to the green dopant. The PYR 1 based green device demonstrated an excellent maximum current efficiency of 48.7 cd/A and external quantum efficiency of 16.4%. Interestingly, the green device with PYR 1 showed an outstanding brightness of 95,870 cd/m2, which is three times greater than that of the reference CBP based device (31,370 cd/m2). The bipolar host PYR 1 is a promising material for high luminescent and low efficiency roll off applications, especially for green PhOLEDs.
Heterocyclic com pounds and organic light-emitting diode including the same
-
Paragraph 0195-0201, (2021/07/27)
The present invention relates to a novel heterocyclic compound and an organic light emitting element including the same as a light-emitting material and, more specifically, to a heterocyclic compound having excellent light emission properties, such as a driving voltage, light emission efficiency, and service life, and an organic light emitting element including the same. Since the heterocyclic compound according to the present invention is more stable compared to conventional materials and has the excellent light emission properties for the driving voltage or current efficiency, and service life, the organic light emitting element including the same can be more stably driven in a low-voltage and light emission efficiency can be improved.
Discovery and mechanism of action studies of 4,6-diphenylpyrimidine-2-carbohydrazides as utrophin modulators for the treatment of Duchenne muscular dystrophy
Vuorinen, Aini,Wilkinson, Isabel V.L.,Chatzopoulou, Maria,Edwards, Ben,Squire, Sarah E.,Fairclough, Rebecca J.,Bazan, Noelia Araujo,Milner, Josh A.,Conole, Daniel,Donald, James R.,Shah, Nandini,Willis, Nicky J.,Martínez, R. Fernando,Wilson, Francis X.,Wynne, Graham M.,Davies, Stephen G.,Davies, Kay E.,Russell, Angela J.
supporting information, (2021/05/03)
Duchenne muscular dystrophy is a fatal disease with no cure, caused by lack of the cytoskeletal protein dystrophin. Upregulation of utrophin, a dystrophin paralogue, offers a potential therapy independent of mutation type. The failure of first-in-class utrophin modulator ezutromid/SMT C1100 in Phase II clinical trials necessitates development of compounds with better efficacy, physicochemical and ADME properties and/or complementary mechanisms. We have discovered and performed a preliminary optimisation of a novel class of utrophin modulators using an improved phenotypic screen, where reporter expression is derived from the full genomic context of the utrophin promoter. We further demonstrate through target deconvolution studies, including expression analysis and chemical proteomics, that this compound series operates via a novel mechanism of action, distinct from that of ezutromid.